Amendments to the Claims:

The following listing of claims replaces all prior versions and listings of claims in the application:

1-46 (Canceled)

- 47. (Currently amended) A polynucleotide comprising a coding sequence for the <u>a</u> multiple epitope fusion antigen of claim 44 comprising the amino acid sequence depicted in Figures 7A-7F, or an amino acid sequence with at least 80% sequence identity thereto which reacts specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.
- 48. (Currently amended) A polynucleotide comprising a coding sequence for the a multiple epitope fusion antigen of claim 45 comprising the amino acid sequence depicted in Figures 7A-7F, or an amino acid sequence with at least 90% sequence identity thereto which reacts specifically with anti-HCV antibodies present in a biological sample from an HCV-infected individual.
- 49. (Currently amended) A polynucleotide comprising a coding sequence for the <u>a</u> multiple epitope fusion antigen of claim 46 consisting of the amino acid sequence depicted in Figures 5A-5F.
 - 50. (Original) A recombinant vector comprising:
 - (a) a polynucleotide according to claim 47;
- (b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.
 - 51. (Original) A recombinant vector comprising:

Atty Dkt No. 2302-16073.10 (PP16073.021)

USSN: DIV of 09/881,239

PATENT

- (a) a polynucleotide according to claim 48;
- (b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.
 - 52. (Original) A recombinant vector comprising:
 - (a) a polynucleotide according to claim 49;
- (b) and control elements operably linked to said polynucleotide whereby the coding sequence can be transcribed and translated in a host cell.
 - 53. (Original) A host cell transformed with the recombinant vector of claim 50.
 - 54. (Original) A host cell transformed with the recombinant vector of claim 51.
 - 55. (Original) A host cell transformed with the recombinant vector of claim 52.
- 56. (Original) A method of producing a recombinant multiple epitope fusion antigen comprising:
 - (a) providing a population of host cells according to claim 53; and
- (b) culturing said population of cells under conditions whereby the multiple epitope fusion antigen encoded by the coding sequence present in said recombinant vector is expressed.
- 57. (Original) A method of producing a recombinant multiple epitope fusion antigen comprising:
 - (a) providing a population of host cells according to claim 54; and
- (b) culturing said population of cells under conditions whereby the multiple epitope fusion antigen encoded by the coding sequence present in said recombinant vector is expressed.
- 58. (Original) A method of producing a recombinant multiple epitope fusion antigen comprising:

Atty Dkt No. 2302-16073.10 (PP16073.021)

USSN: DIV of 09/881,239

PATENT

(a) providing a population of host cells according to claim 55; and

(b) culturing said population of cells under conditions whereby the multiple epitope fusion antigen encoded by the coding sequence present in said recombinant vector is expressed.